Document Detail


Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas.
MedLine Citation:
PMID:  17278092     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Colorectal cancer (CRC) forms through a series of histologic steps that are accompanied by mutations and epigenetic alterations, which is called the polyp-cancer sequence. The role of epigenetic alterations, such as aberrant DNA methylation, in the polyp-cancer sequence in sporadic CRC and particularly in hereditary colon cancer is not well understood. Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14(ARF) in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit" mechanism in CRC and to characterize the role of DNA methylation in the polyp phase of the Lynch syndrome. We found MLH1 and p14(ARF) are methylated in 53 and 60% of the Lynch syndrome adenomas and in 4 and 20% of sporadic adenomas, whereas CDKN2A/p16 and MGMT are methylated in 6 and 14% of the Lynch syndrome adenomas versus 50 and 64% of sporadic adenomas. Therefore, the frequency and pattern of gene methylation varies between the Lynch syndrome and sporadic colon adenomas, implying differences in the molecular pathogenesis of the tumors. MLH1 methylation in the Lynch syndrome adenomas suggests gene methylation might have a role in the initiation of these neoplasms.
Authors:
Andrew Kaz; Young-Ho Kim; Slavomir Dzieciatkowski; Henry Lynch; Patrice Watson; Mary Kay Washington; Li Lin; William M Grady
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  120     ISSN:  0020-7136     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-03-08     Completed Date:  2007-04-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1922-9     Citation Subset:  IM    
Copyright Information:
(c) 2007 Wiley-Liss, Inc.
Affiliation:
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adaptor Proteins, Signal Transducing
Adenoma / genetics*
Adult
Aged
Carrier Proteins / genetics
Colonic Neoplasms / genetics*
Colorectal Neoplasms, Hereditary Nonpolyposis / etiology,  genetics*
DNA Methylation*
DNA Modification Methylases
DNA Repair Enzymes
Female
Genes, p16
Humans
Loss of Heterozygosity
Male
Middle Aged
Nuclear Proteins / genetics
Tumor Suppressor Protein p14ARF / genetics
Tumor Suppressor Proteins
Chemical
Reg. No./Substance:
0/Adaptor Proteins, Signal Transducing; 0/Carrier Proteins; 0/MLH1 protein, human; 0/Nuclear Proteins; 0/Tumor Suppressor Protein p14ARF; 0/Tumor Suppressor Proteins; EC 2.1.1.-/DNA Modification Methylases; EC 2.1.1.63/MGMT protein, human; EC 6.5.1.-/DNA Repair Enzymes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Smoking and survival after breast cancer diagnosis.
Next Document:  Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients.